key: cord-0747326-q600lkpm
authors: Pérez-Fernández, Xosé L; Sabater-Riera, Joan; Fuset-Cabanes, MariPaz
title: COVID-19 ARDS: getting ventilation right
date: 2021-12-31
journal: Lancet
DOI: 10.1016/s0140-6736(21)02439-9
sha: 2982023135e9ceba80cae6a542a856e16317ef0d
doc_id: 747326
cord_uid: q600lkpm

nan

www.thelancet.com Vol 399 January 1, 2022

We thank Xosé Pérez-Fernández and colleagues for their thoughtful Correspondence regarding our study of extracorporeal membrane oxygenation (ECMO) in COVID-19. 1 We agree that our study does not provide evidence that forms of non-invasive ventilation (NIV), such as high-flow nasal cannula and mask or helmet ventilation, might be deleterious compared with other strategies. Our observational study was not designed to make causal inferences regarding the potential superiority of ECMO or any pre-ECMO support strategy. We showed that the more recent cohort with higher mortality had increased use of NIV and decreased duration of pre-ECMO invasive mechanical ventilation (IMV). 1 We did not measure the initiation time of NIV, however, and so could not test for an association between duration of pre-ECMO NIV and the relative risk of mortality. Although many patients with severe COVID-19 might benefit from the use of NIV, the subset of patients who ultimately do not respond to NIV and require IMV are precisely those who are likely to have high work of breathing, high transpulmonary pressures, and who are therefore at risk of developing patient self-inflicted lung injury. 2 This situation might select for more severely ill patients receiving IMV and ultimately ECMO. It is one hypothesis out of a number we put forward to help explain the association with increased mortality in those who ultimately do not respond to these levels of support. However, this is not an argument for or against the use of NIV in this setting. Even if the hypothesis is correct, NIV might still be the appropriate therapy for any given patient. A randomised clinical trial is required to fully address this question.

To date, there are no prospective clinical trials evaluating the effect on outcomes of the timing of initiating ECMO support. However, in accord with the suggestion of And second, when to start ECMO on these patients has probably changed during this period due to a higher use of NIV (the authors do not report days on NIV before intubation). We had never before ventilated so many patients with severe ARDS and we have learned that a so-called wait and see approach in terms of intubation or ECMO, as with many other invasive procedures in critically ill patients, 4 might also be valid. ECMO should be initiated in those patients who cannot be protectively ventilated in the context of extremely severe ARDS. 5 In this scenario, mortality might increase in those patients who finally require ECMO assuming that this delayed strategy will save many more other patients from receiving an intervention that is not free from complications besides its high cost of resources.

We declare no competing interests. 

We read with special interest the Article by Ryan Barbaro and colleagues, 1 describing the evolving outcomes of patients with COVID-19 who required extracorporeal membrane oxygenation (ECMO) during 2020. We were sad to corroborate the same increased mortality we had observed in our own patients. However, we wish to clarify two key aspects that we hope will supplement the conclusions of this important Article. First, the assumption that a noninvasive ventilation (NIV) strategy can be deleterious for patients with acute respiratory distress syndrome (ARDS) and with COVID-19 has no clinical evidence so far. 2 Furthermore, NIV has been progressively used during the evolving pandemic and is probably more related to the improvement in survival observed in hospitalised patients than to a delay in intubation and hypothetically worse outcome. 3 

Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK

Initiation strategies for renal-replacement therapy in the intensive care unit

Extracorporeal Life Support Organization coronavirus disease 2019 interim guidelines: a consensus document from an International Group of Interdisciplinary Extracorporeal Membrane Oxygenation Providers

UK government secures groundbreaking COVID-19 antivirals

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients

Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat

Induction effects of ritonavir: implications for drug interactions

The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters

British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy